Our approach provides the only protein-based means to target the RNA in cancer cells. Our EVade™ ribonucleases have selectivity for cancer cells due to their affinity for the anionic glycans that are overexpressed in cancer. Our lead candidate, called QBI-139, has a strong therapeutic window against a variety of in vivo solid tumors in xenograft models including: colon, non-small cell lung, ovarian, pancreatic and prostate cancer. A first in human, dose escalation Phase I trial in patients with solid tumors showed that QBI-139 has a favorable safety profile, without the common side effects of chemotherapies (e.g. myelosuppression). At the higher dose levels, QBI-139 showed an increased rate of stable disease as well as changes in serum markers for two prostate cancer patients.
See where Quintessence Biosciences is presenting in the coming months.